APOC3-Targeting Modified Oligonucleotides for Potent RNA Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent therapeutic agents to reduce ApoCIII levels and triglycerides in patients at risk for or with cardiovascular diseases, as existing treatments like olezarsen are not commercially approved, and current agents targeting APOC3 are insufficient.
Innovation Solution
Development of oligomeric duplexes and modified oligonucleotides that are complementary to APOC3 RNA, comprising modified sugar moieties and internucleoside linkages, to reduce APOC3 expression and ApoCIII protein levels, using agents such as antisense oligonucleotides and RNAi agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic agents like olezarsen are used to reduce APOC3 expression, then ApoCIII levels and triglycerides decrease, but these agents are not commercially approved and insufficient for clinical use
Solution Approach 1:
The patent modifies oligonucleotide parameters including sugar moiety composition (2'-O-methoxyethyl modifications), internucleoside linkage types (phosphorothioate, phosphodithioate), and sequence composition to create optimized agents with improved stability, potency, and pharmacokinetic properties suitable for commercial development
Solution Approach 2:
The invention creates composite oligomeric duplexes combining modified oligonucleotides with specific structural features (overhangs, gap regions, conjugated groups) to achieve both therapeutic efficacy and manufacturability for clinical use
2Reliability
If modified oligonucleotides with multiple modified sugar moieties are used to reduce APOC3 RNA, then therapeutic effect increases, but manufacturing complexity increases
Solution Approach 1:
The patent applies modified sugar moieties at specific local positions within the oligonucleotide sequence rather than uniformly throughout, optimizing therapeutic effect while controlling manufacturing complexity through strategic placement of modifications
Solution Approach 2:
The invention systematically varies parameters including the type of sugar modification (2'-O-methoxyethyl), the position of modifications, and the ratio of modified to unmodified nucleosides to achieve optimal balance between efficacy and manufacturability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified oligonucleotides effectively decrease APOC3 RNA and ApoCIII protein levels, providing therapeutic options for conditions like hypertriglyceridemia, pancreatitis, and atherosclerotic cardiovascular disease by ameliorating symptoms and preventing disease progression.
Implementation Method 1
oligomeric duplexes and modified oligonucleotides that are complementary to APOC3 RNA
Implementation Method 2
complementary to APOC3 RNA, comprising modified sugar moieties and internucleoside linkages
Data Source
AI summary
Provided are oligomeric agents, methods, and pharmaceutical compositions for reducing the amount or activity of APOC3 RNA in a cell or animal, and in certain instances reducing the amount of ApoCIII protein in a cell or animal. Such oligomeric agents, methods, and pharmaceutical compositions are useful to treat or manage hypertriglyceridemia and/or cardiovascular disease (CVD).